title: Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction.
abstract: In patients who have ST-segment elevation myocardial infarction (STEMI), a patent infarct-related artery on the initial angiogram is associated with improved clinical outcomes, including decreased mortality. The present study assessed the influence of administering aspirin, beta blockers, statins, and angiotensin-converting enzyme inhibitors before STEMI on infarct-related artery patency. Our data demonstrate that patients who have STEMI and receive these medications on an outpatient basis before the event have a higher likelihood of having a patent infarct-related artery compared with patients who do not receive these medications. Further, our data demonstrate a graded association according to the number of such medications being administered: the likelihood of a patent infarct-related artery increased to >50% as the number of these medications increased.
authors.affiliation: The Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
authors.forename: Christina R
authors.initials: CR
authors.lastname: Robinson
authors.forename: Justin L
authors.initials: JL
authors.lastname: Martin
authors.forename: Lily
authors.initials: L
authors.lastname: Zhang
authors.forename: Russell M
authors.initials: RM
authors.lastname: Canham
authors.forename: Shuaib M
authors.initials: SM
authors.lastname: Abdullah
authors.forename: Joaquin E
authors.initials: JE
authors.lastname: Cigarroa
authors.forename: L David
authors.initials: LD
authors.lastname: Hillis
authors.forename: Sabina A
authors.initials: SA
authors.lastname: Murphy
authors.forename: Darren K
authors.initials: DK
authors.lastname: McGuire
authors.forename: James A
authors.initials: JA
authors.lastname: de Lemos
authors.forename: Ellen C
authors.initials: EC
authors.lastname: Keeley
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000503:physiopathology; D003331:Coronary Vessels / Q000503:physiopathology*; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000503:physiopathology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D014336:Troponin / Q000097:blood; D014654:Vascular Patency / Q000502:physiology*
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D014336:Troponin; D001241:Aspirin